213 related articles for article (PubMed ID: 33895186)
1. Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know.
Odi R; Invernizzi RW; Gallily T; Bialer M; Perucca E
Pharmacol Ther; 2021 Oct; 226():107866. PubMed ID: 33895186
[TBL] [Abstract][Full Text] [Related]
2. Comparative activity of the enantiomers of fenfluramine and norfenfluramine in rodent seizure models, and relationship with their concentrations in plasma and brain.
Erenburg N; Hamed R; Shaul C; Perucca E; Bialer M
Epilepsia; 2023 Jun; 64(6):1673-1683. PubMed ID: 36995363
[TBL] [Abstract][Full Text] [Related]
3. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
[TBL] [Abstract][Full Text] [Related]
4. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
[TBL] [Abstract][Full Text] [Related]
5. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
6. Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ; Chin RFM
Expert Rev Neurother; 2024 Mar; 24(3):235-249. PubMed ID: 38315124
[TBL] [Abstract][Full Text] [Related]
7. Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?
Bialer M; Perucca E
CNS Drugs; 2022 Feb; 36(2):113-122. PubMed ID: 35094259
[TBL] [Abstract][Full Text] [Related]
8. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
Frampton JE
Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
[TBL] [Abstract][Full Text] [Related]
9. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
Sullivan J; Simmons R
Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective Analysis of the Antiseizure Activity of Fenfluramine and Norfenfluramine in Mice: Is
Erenburg N; Perucca E; Bechard J; Dube C; Weishaupt N; Sherrington R; Bialer M
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473769
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis.
Tabaee Damavandi P; Fabin N; Giossi R; Matricardi S; Del Giovane C; Striano P; Meletti S; Brigo F; Trinka E; Lattanzi S
Neurol Ther; 2023 Apr; 12(2):669-686. PubMed ID: 36853503
[TBL] [Abstract][Full Text] [Related]
12. Fenfluramine acts as a positive modulator of sigma-1 receptors.
Martin P; de Witte PAM; Maurice T; Gammaitoni A; Farfel G; Galer B
Epilepsy Behav; 2020 Apr; 105():106989. PubMed ID: 32169824
[TBL] [Abstract][Full Text] [Related]
13. Fenfluramine as antiseizure medication for epilepsy.
Gogou M; Cross JH
Dev Med Child Neurol; 2021 Aug; 63(8):899-907. PubMed ID: 33565102
[TBL] [Abstract][Full Text] [Related]
14. Failure to use new breakthrough treatments for epilepsy.
Klein P; Krauss GL; Steinhoff BJ; Devinsky O; Sperling MR
Epilepsia; 2023 Jun; 64(6):1458-1465. PubMed ID: 36855241
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L; Li W; Wang C
Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
Knupp KG; Scheffer IE; Ceulemans B; Sullivan JE; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Shore S; Agarwal A; Lock M; Farfel GM; Galer BS; Gammaitoni AR; Davis R; Gil-Nagel A
JAMA Neurol; 2022 Jun; 79(6):554-564. PubMed ID: 35499850
[TBL] [Abstract][Full Text] [Related]
17. A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome.
Lagae L; Schoonjans AS; Gammaitoni AR; Galer BS; Ceulemans B
Epilepsia; 2018 Oct; 59(10):1881-1888. PubMed ID: 30146701
[TBL] [Abstract][Full Text] [Related]
18. Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.
Sullivan J; Lagae L; Cross JH; Devinsky O; Guerrini R; Knupp KG; Laux L; Nikanorova M; Polster T; Talwar D; Ceulemans B; Nabbout R; Farfel GM; Galer BS; Gammaitoni AR; Lock M; Agarwal A; Scheffer IE;
Epilepsia; 2023 Oct; 64(10):2653-2666. PubMed ID: 37543865
[TBL] [Abstract][Full Text] [Related]
19. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
20. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.
Polster T
Epilepsy Behav; 2019 Feb; 91():99-102. PubMed ID: 30269941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
